Enhertu May Further Improve Survival Versus Xeloda Regimens in HER2-Positive Breast Cancer
Patients with advanced HER2-positive unresectable and/or metastatic breast cancer who were previously treated had a 34% reduction in death and a 13-month average increase in survival when treated with Enhertu (fam-trastuzumab-deruxtecan-nxki) versus a Xeloda (capecitabine)-based regimen, according to recent trial results.